Chronic immune thrombocytopenia, or cITP, is a disorder that can lead to excessive bruising or bleeding.
What is cITP?
cITP can develop when your immune system attacks certain blood cells (platelets) in your blood. Platelets help the blood to clot. Patients with cITP have low levels of platelets and are at risk of excessive bruising or bleeding.
How cITP is treated
cITP is typically treated by increasing platelet counts with an intravenous immunoglobulin (IVIg), such as PANZYGA.
A nurse or other member of your treatment team will administer PANZYGA through an infusion in a vein, which can occur in a hospital, an infusion clinic, or at home.
In a clinical study, adult patients treated with PANZYGA had an increase in the number of platelets (a type of blood cell) and decrease in bleeding.
- For adult patients who responded to treatment with PANZYGA, it took about 2 days to achieve an increase in the number of platelets, and the increase lasted for 14 days
Adult patients treated with PANZYGA had a decrease in bleeding.
- After 7 days in the study, 14% of patients had bleeding compared with 64% of patients having bleeding prior to the study
Adverse events reported in >5% of the 40 adult patients with cITP treated with PANZYGA in a study
The most common side effects of PANZYGA in the cITP clinical study were headache, fever, nausea, vomiting, dizziness, and anemia. Allergic reactions may occur.
Learn more here. When you have questions, it’s best to talk with your healthcare professional. In addition, please find some frequently asked questions and answers.
Help with managing your condition. PANZYGA offers a variety of downloadable resources with information about treatment, including guides to keep track of your therapy, and more.
All in one place. Pfizer IGuide™ can help you understand your insurance coverage and out-of-pocket costs for your prescribed PANZYGA, as well as identify financial assistance options for which you may be eligible.
Learn more. A free mobile app designed to help support the treatment experience for patients.
Sign up for additional information to help you understand more about PANZYGA and to receive free resources.